KR20190048323A - Ginsenoside composition for treating, improving, or preventing inflammatory disease, and method for preparing the same - Google Patents

Abstract

The present invention relates to a ginsenoside composition for treating, alleviating, or preventing inflammatory diseases containing a ginseng extract, in which 30 to 70 wt% of a total ginsenoside content is contained and 0.01 to 4 wt% of a Rg3 content is contained relative to the total ginsenoside weight. A ginseng extract composition of the present invention has an increased content of ginsenoside by the treatment of ginsenoside glycosidase, consisting of an amino acid sequence of sequence number 1, and has a relatively increased content of minor saponins in ginsenoside, thereby being able to improve antioxidant, anti-inflammatory, and anti-aging functions.

Description

FIELD OF THE INVENTION [0001] The present invention relates to a ginsenoside composition for the treatment, improvement or prevention of inflammatory diseases and a method for producing the ginsenoside composition,

The present invention relates to a ginsenoside composition and a method for preparing the same, and more particularly, to a ginsenoside composition which metabolizes ginsenoside of a conventional ginseng to obtain new compositions whose physiological activities are different from those of a previous ginseng, ≪ / RTI > to a method of obtaining an effective composition.

The saponin component containing the major physiologically active component of ginseng or red ginseng is different in chemical structure from the saponin found in other plants and it is named ginsenoside in particular as a ginseng glycoside . Such ginsenosides may be classified as protopanaxadiol-type, protopanaxatriol-type, and oleanolic acid-type ginsenosides according to the structure of aglycone. And the like. These three groups are again the positions of the sugar moieties (aglycones) attached by glycoside bonds at the C-3, C-6 and C-20 positions of the ring in the compound structure and the number Rg1, Re, Rb1, Rc and Rb2 are major ginsenosides which account for more than 90% of total saponins (Park, 2004), and they are orally administered to the human body due to its large size , It is known that it is difficult to be directly absorbed. Thus, these major ginsenosides require a conversion process that deglycosylates sugars to effectively represent their physiological activity in in vivo tests (Tawab et al., 2003; Akao et al. 1998). On the other hand, in recent decades, excellent pharmacological effects of ginsenosides having a minor form such as Rg3, Rh2 and compound K have been revealed. As the results of these studies were published, it was found that the ginsenosides F2, Rg3, Rh1, Rh2 and compounds K (compound K, CK), Gyp17, Rg3, C-Mc1, C- Minor ginsenosides have been extensively studied, and a method for increasing the content ratio of certain ginsenosides having such a minor form has been desired.

  (De Mayo et al., Canad. J. Chem., 43, 2033, 1965), an enzymatic method (Kitagawa et al., Terahedron Letters, 30, 2283, 1974), and a method using glycoside synthesis (No. 10-2005-0007250) have been proposed. However, the above-mentioned methods require 1) several steps in the manufacturing process, or 2) 3) the use of an inadequate catalyst for edible purposes, and 4) low yields, which still have limitations in mass production.

  Among the enzymatic methods, the types of enzymes that can be used include ginsenoside glycosidase,? -L-arabinopyranosidase,? -L-arabinofuranosidez it has been reported that enzymes such as? -L-arabinofuranosidase and? -L-rhamnosidase biotransformation of major ginsenosides such as Rb1, Rb2, Rc and Re . In other words, saponins extracted from ginseng are mostly composed of complex saponins such as Rg1, Re, Rb1, Rb2, Rc and Rb3, so that the number, type and position of sugars bound by glycosidic bonds are different A large amount of various enzymes are required.

Korean Patent Publication No. 10-2016-0086498 Korean Patent Registration No. 10-1647631

It is an object of the present invention to provide a method for biosynthesizing ginsenoside, which is major saponin contained in ginseng in natural state, into ginsenoside glycosidease having a specific amino acid sequence, so that the total ginsenoside content is remarkably high, The present invention provides a ginsenoside composition for treating, ameliorating or preventing an inflammatory disease comprising an extract of ginseng having a high content of minor saponins having high physiological activity as an active ingredient.

According to an aspect of the present invention,

The present invention relates to a ginseng extract containing 30 to 70% by weight of total ginsenoside and 0.01 to 4% by weight of Rg3 relative to the total ginsenoside weight as an active ingredient. Senoside compositions are provided.

The ginsenoside composition may contain 2 to 30% by weight of any one selected from Gyp17, Rg3, C-Mc1, C-Mx1 and F2 based on the total ginsenoside weight.

The ginsenoside composition is characterized in that the sum of the weights of Gyp17, Rg3, C-Mc1, C-Mx1 and F2 is 30 to 80% by weight based on the total ginsenoside weight.

The ginsenoside composition may be a pharmaceutical composition for the treatment or prevention of inflammation, or a food composition for improving or preventing inflammatory diseases.

Wherein said inflammatory disease is selected from the group consisting of inflammatory skin diseases, Crohn's disease, ulcerative colitis, peritonitis, osteomyelitis, meningitis, meningitis, encephalitis, pancreatitis, trauma-induced shock, bronchial asthma, allergic rhinitis, cystic fibrosis, stroke, acute bronchitis, Osteoarthritis, gouty arthritis, systemic lupus erythematosus, recurrent fever, psoriasis, post-infectious arthritis, gonococcal arthritis, tuberculosis, osteoarthritis, osteoarthritis, gout, spondyloarthropathies, ankylosing spondylitis, Arthritis, arthritis, arthritis, viral arthritis, fungal arthritis, rheumatoid arthritis, rheumatoid multiple myalgia, arthropathic arthritis, calcium crystalloid arthropathy, non-articular rheumatism, bursitis, hay fever, and hemochromatosis.

According to another aspect of the present invention,

(a) preparing ginseng extract by extracting ginseng with water, a lower alcohol having 1-4 carbon atoms, or a mixed solvent of the lower alcohol and water; And (b) enzymatically treating the ginseng extract with ginsenoside glycosidease comprising the amino acid sequence of SEQ ID NO: 1. A method for making a synobic composition is provided.

Wherein at least one selected from the group consisting of ginsenosides Re, Rb1, Rc, Rb2, Rb3 and Rd is partially or totally converted into Gyp17, Rg3, C-Mc1, C-Mx1 and F2 .

The ginsenoside composition for treating, ameliorating or preventing an inflammatory disease comprising the ginseng extract of the present invention as an active ingredient can be prepared by mixing ginsenoside, major saponin contained in natural ginseng, with ginsenoside glycoside having a specific amino acid sequence The total ginsenoside content is remarkably high due to biotransformation by sea sate, and the minor saponin content of total ginsenosides is increased to increase the physiological activity, thereby improving antioxidation, anti-inflammation and anti-aging function.

Figure 1 shows ginsenoside size markers.
2 shows the results of HPLC analysis showing the ginsenoside component before the reaction.
Figure 3 shows the results of HPLC analysis of ginsenoside components after reaction with ginsenoside glycosides.
4 is a cytotoxicity test result of the ginsenoside composition of Example 1. Fig.
Fig. 5 shows the results of TNF-a expression measurement test on the ginsenoside composition of Example 1. Fig.
Fig. 6 shows the results of the measurement of IL-6 expression in the ginsenoside composition of Example 1. Fig.
Fig. 7 is a test result of inhibition of formation of nitric oxide (NO) on the ginsenoside composition of Example 1. Fig.
Figure 8 is the amino acid sequence of the ginsenoside glycosidease used in the present invention.

BRIEF DESCRIPTION OF THE DRAWINGS The present invention is capable of various modifications and various embodiments, and specific embodiments are illustrated in the drawings and described in detail in the detailed description. It is to be understood, however, that the invention is not to be limited to the specific embodiments, but includes all modifications, equivalents, and alternatives falling within the spirit and scope of the invention. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS Hereinafter, the present invention will be described in detail with reference to the accompanying drawings.

Hereinafter, the ginsenoside composition for the treatment, improvement or prevention of the inflammatory disease of the present invention will be described.

The ginsenoside composition of the present invention is characterized in that the total ginsenoside content is 30 to 70% by weight, and the ginseng extract having an Rg3 content of 0.01 to 4% by weight based on the total ginsenoside weight is included as an active ingredient .

It is preferable that the ginsenoside composition contains 2 to 30% by weight of any one selected from Gyp17, Rg3, C-Mc1, C-Mx1 and F2 based on the total ginsenoside weight.

It is preferable that the ginsenoside composition has a total weight of Gyp17, Rg3, C-Mc1, C-Mx1 and F2 of 30 to 80% by weight based on the total ginsenoside weight.

The ginsenoside composition may be a pharmaceutical composition for treating or preventing an inflammatory disease, or a food composition for improving or preventing an inflammatory disease.

Wherein said inflammatory disease is selected from the group consisting of inflammatory skin diseases, Crohn's disease, ulcerative colitis, peritonitis, osteomyelitis, meningitis, meningitis, encephalitis, pancreatitis, trauma-induced shock, bronchial asthma, allergic rhinitis, cystic fibrosis, stroke, acute bronchitis, Osteoarthritis, gouty arthritis, systemic lupus erythematosus, recurrent fever, psoriasis, post-infectious arthritis, gonococcal arthritis, tuberculosis, osteoarthritis, osteoarthritis, gout, spondyloarthropathies, ankylosing spondylitis, Arthritis, arthritis, arthritis, viral arthritis, fungal arthritis, rheumatoid arthritis, rheumatoid multiple myalgia, arthropathic arthritis, calcium crystalloid arthropathy, non-articular rheumatism, bursitis, hay fever, hemochromatosis etc., It is not limited.

Hereinafter, a method for producing a ginsenoside composition for the treatment, improvement or prevention of the inflammatory disease of the present invention will be described.

First, Carbon number  1-4, or a mixed solvent of the lower alcohol and water to prepare a ginseng extract (step a).

The extraction solvent used in the present invention is preferably water, a lower alcohol having from 1 to 4 carbon atoms, or a mixed solvent of the lower alcohol and water. However, the scope of the present invention is not limited thereto, and acetone, ethyl acetate, Chloroform, butyl acetate, 1,3-butylene glycol, hexane, diethyl ether and the like may be used.

As used herein, the term 'extract' has the meaning of being used as a crude extract in the art, but broadly it can also include fractions in which the extract is further fractionated. It may also be prepared in powder form by further processes such as vacuum distillation and lyophilization, or spray drying.

Thereafter, the ginseng extract is treated with the amino acid sequence of SEQ ID NO: Gin Senocide By Glicosy Days  Enzyme treatment (step b).

The amino acid sequence of the ginsenoside glycosides is shown in Fig.

Wherein at least one selected from the group consisting of ginsenosides Re, Rb1, Rc, Rb2, Rb3 and Rd is partially or totally converted into Gyp17, Rg3, C-Mc1, C-Mx1 and F2 .

As a result, the ginsenoside content in the ginseng extract is remarkably increased to 3 to 7 times, and the minor saponins, Gyp17, Rg3, C-Mc1, C-Mx1 and F2 having high physiological activity among total ginsenosides are produced, Anti-inflammatory, anti-aging function can be remarkably improved.

In the present specification, the term 'comprising as an active ingredient' means an amount sufficient to achieve the efficacy or activity of the ginsenoside composition. In one embodiment of the invention, the ginsenoside composition in the composition of the present invention is administered in an amount of, for example, 0.001 mg / kg or more, preferably 0.1 mg / kg or more, more preferably 1 mg / Preferably 10 mg / kg or more. Since the ginsenoside composition has no adverse effect on the human body even when it is administered in an excessive amount as a natural product, the quantitative upper limit of the ginsenoside composition contained in the composition of the present invention can be selected by a person skilled in the art within a suitable range.

The pharmaceutical composition of the present invention may be prepared by using pharmaceutically acceptable and physiologically acceptable adjuvants in addition to the above-mentioned active ingredients. Examples of the adjuvants include excipients, disintegrants, sweeteners, binders, coating agents, swelling agents, lubricants, Or a flavoring agent may be used.

The pharmaceutical composition may be formulated into a pharmaceutical composition containing at least one pharmaceutically acceptable carrier in addition to the above-described active ingredients for administration.

The pharmaceutical form of the pharmaceutical composition may be a granule, a powder, a tablet, a coated tablet, a capsule, a suppository, a liquid, a syrup, a juice, a suspension, an emulsion, a drip agent or an injectable liquid agent. For example, for formulation into tablets or capsules, the active ingredient may be combined with an oral, non-toxic pharmaceutically acceptable inert carrier such as ethanol, glycerol, water, and the like. Also, if desired or necessary, suitable binders, lubricants, disintegrants and coloring agents may also be included as a mixture. Suitable binders include, but are not limited to, natural sugars such as starch, gelatin, glucose or beta-lactose, natural and synthetic gums such as corn sweeteners, acacia, tracker candles or sodium oleate, sodium stearate, magnesium stearate, sodium Benzoate, sodium acetate, sodium chloride, and the like. Disintegrants include, but are not limited to, starch, methyl cellulose, agar, bentonite, xanthan gum and the like.

Acceptable pharmaceutical carriers for compositions that are formulated into a liquid solution include sterile water and sterile water suitable for the living body such as saline, sterile water, Ringer's solution, buffered saline, albumin injection solution, dextrose solution, maltodextrin solution, glycerol, And other conventional additives such as an antioxidant, a buffer, and a bacteriostatic agent may be added as needed. In addition, diluents, dispersants, surfactants, binders, and lubricants may be additionally added to formulate into injectable solutions, pills, capsules, granules or tablets such as aqueous solutions, suspensions, emulsions and the like.

The pharmaceutical composition of the present invention can be administered orally or parenterally. In the case of parenteral administration, it can be administered by intravenous injection, subcutaneous injection, muscle injection, intraperitoneal injection, transdermal administration, etc., preferably oral administration.

The appropriate dosage of the pharmaceutical composition of the present invention varies depending on factors such as the formulation method, administration method, age, body weight, sex, pathological condition, food, administration time, route of administration, excretion rate and responsiveness of the patient, , A skilled physician can readily determine and prescribe dosages effective for the desired treatment or prophylaxis. According to a preferred embodiment of the present invention, the daily dose of the pharmaceutical composition of the present invention is 0.0001-10 g / kg.

The pharmaceutical composition of the present invention may be prepared in a unit dose form by formulating it using a pharmaceutically acceptable carrier and / or excipient according to a method which can be easily carried out by a person having ordinary skill in the art to which the present invention belongs Into a multi-dose container. The formulations may be in the form of solutions, suspensions or emulsions in oils or aqueous media, or in the form of excipients, powders, granules, tablets or capsules, and may additionally contain dispersing or stabilizing agents.

The food composition according to the present invention can be used as a functional food or added to various foods. Foods to which the composition of the present invention can be added include, for example, beverages, alcoholic beverages, confectionery, diet bars, dairy products, meats, chocolates, pizza, breads, noodles, gums, ice creams, And food.

The food composition of the present invention may contain not only the ginsenoside composition as an active ingredient, but also ingredients normally added in the course of food production, including, for example, proteins, carbohydrates, fats, nutrients, flavoring agents and flavoring agents do. Examples of the above-mentioned carbohydrates are monosaccharides such as glucose, fructose, and the like; Disaccharides such as maltose, sucrose, oligosaccharides and the like; And polysaccharides such as dextrin, cyclodextrin and the like, and sugar alcohols such as xylitol, sorbitol and erythritol. Natural flavorings such as tau martin and stevia extract (e.g., rebaudioside A and glycyrrhizin) and synthetic flavorings (saccharine, aspartame, etc.) can be used as flavorings. For example, when the food composition of the present invention is prepared from a drink and a beverage, citric acid, liquid fructose, sugar, glucose, acetic acid, malic acid, juice, various plant extracts and the like may be further added in addition to the ginsenoside composition.

The present invention provides a health functional food comprising the ginsenoside composition as an active ingredient. A health functional food is a food prepared by adding a ginsenoside composition to a food material such as a beverage, a tea, a spice, a gum, or a confection, or encapsulated, powdered, or suspended therein. However, unlike general medicine, there is an advantage that there is no side effect that can occur when a long-term use of the medicine is performed using the food as a raw material. The health functional food of the present invention thus obtained is very useful because it can be ingested routinely. The amount of the ginsenoside composition to be added to such a health functional food can not be uniformly determined depending on the kind of the health functional food to which it is added but may be added within a range that does not deteriorate the original taste of the food, And usually ranges from 0.01 to 50% by weight, preferably from 0.1 to 20% by weight. In the case of health functional foods in the form of pills, granules, tablets or capsules, they may be added usually in the range of 0.1 to 100% by weight, preferably 0.5 to 80% by weight. In one embodiment, the health functional food of the present invention may be in the form of a pill, tablet, capsule or beverage.

[Example]

Example  One: Gin Senocide  Biotransformation

Ginseng was purchased as red ginseng (Daedong KOREA, Korea), and saponin was extracted using ethanol. The extracted saponin was dissolved by using tertiary purified water. The reaction was carried out in a solution of 50 mM phosphate buffer (pH 7.0) containing ginsenoside glycosidase: substrate = 1: 4,000 (mole ratio , And Molar Ratio), and the reaction was carried out in a shaking incubator at 37 ° C for one day. After completion of the reaction, the mixture was concentrated to 30 to 50% of the initial reaction volume using a rotary evaporator (R300, BUCHI). The concentrate was again mixed with the same amount of n-butanol, and the mixture was centrifuged using a centrifuge. The supernatant was separately separated and the solvent was evaporated by centrifugation under low-temperature vacuum (Speed Vac. Drying). The dried reactants were pulverized using a mixer and powdered and dried separately in a dryer at 60 ° C for 48 hours.

[Test Example]

Test Example  1: Biological conversion confirmation

Separately dried reactants according to Example 1 were subjected to composition analysis using HPLC (High Performance Liquid Chromatography). Figure 1 shows ginsenoside size markers. The ginsenoside components before and after the reaction with the ginsenoside glycosides were shown in the following Tables 1 and 2, and the ginsenoside components after the reaction with the ginsenoside glycosides were shown in Table 2 below Respectively.

Ginsenoside Glycoxidase Reaction Ginseng Extract Composition Title Retention Time (min.) Area Ratio (%) Content (%) Component Ratio (%) Area Ratio (%) Components CH 1 1.2333 43.67 52.36 77.41 Carbohydrates (CH) CH 2 1.7000 4.88 5.85 CH 3 1.8500 16.01 19.20 Re 4.4000 0.67 0.80 11.65 6.89 Ginsenosides Rb1 4.8800 3.56 4.27 36.63 Rc 5.1667 2.48 2.97 25.51 Rb2 / 3 5.4333 2.09 2.51 21.50 Rd 6.0333 0.92 1.10 9.47 Gyp17 0.00 0.00 C- Mc1 0.00 0.00 C- Mx1 0.00 0.00 F2 0.00 0.00 Rg3 0.00 0.00 Unknown1 12.9833 0.58 0.70 10.94 Lipid Unknown2 13.9167 1.74 2.09 Unknown3 15.6167 6.80 8.15 Sum 83.40 100.00 100.00

Ginsenosides Ginseng Extract Composition after Glucosidase Reaction Title Retention Time (min.) Area Ratio (%) Content (%) Component Ratio (%) Area Ratio (%) Components CH 1 1.2833 6.78 9.23 34.61 Carbohydrates (CH) CH 2 1.6833 9.91 13.49 CH 3 1.8500 8.73 11.89 Re 4.3667 1.09 1.48 47.96 3.09 Ginsenosides Rb1 4.8667 3.56 4.85 10.11 Rc 5.2333 3.63 4.94 10.31 Rb2 / 3 5.5500 4.17 5.68 11.84 Rd 6.1833 2.59 3.53 7.35 Gyp17 6.6167 6.76 9.20 19.19 C- Mc1 7.0167 2.99 4.07 8.49 C- Mx1 7.2667 4.12 5.61 11.70 F2 8.2167 5.53 7.53 15.70 Rg3 9.9333 0.78 1.06 2.21 Unknown1 12.8333 1.78 2.42 17.43 Lipid Unknown2 13.7833 2.31 3.15 Unknown3 15.5167 8.71 11.86 Sum 73.44 100.00 100.00

The ginsenoside content in the ginseng extract was increased from 11.65% to 47.96% more than 4 times. In addition, the composition of ginsenoside showed minor saponins Gyp17, Rg3, C-Mc1, C-Mx1, The biosynthesis of F2 resulted in a significant change in the components of senosides.

Test Example  2: Gin Senocide  Efficacy test

Example 2 in using the saponin samples prepared according to the test tube on the antioxidant, anti-inflammatory and anti-aging effect (in vitro experiments were conducted.

(1) Cytotoxicity test

Macrophage RAW264.7 was treated with 1 μg / ml of LPS (lipopolysaccharide) and the untreated cells were divided into 96-well plates at 1 × 10 ⁴ cells / well and cultured for 8 hours. After the incubation, the medium was replaced with a new culture medium (DMEM (Eagle's minimal essential medium) medium containing 10% fetal bovine serum and 1% penicillin), and the ginsenoside composition of Example 1 was replaced with 1.3, 2.5 , 5, 10 / / ml and cultured for 24 hours. After incubation, 10 占 퐇 of WST solution was added to each well, followed by reaction in a cell incubator for 30 minutes. Then, the absorbance at 450 nm was measured to show the cell survival rate as a percentage in the control group. The results are shown in FIG. . According to this, it was confirmed that the cell survival rate was increased by the treatment of the ginsenoside complex of Example 1, and therefore, no cytotoxicity was observed.

(2) Measurement of TNF-α expression

RAW264.7 cells treated or not treated with LPS were cultured in the same manner as described above, and the culture medium and cells were placed in a 1 ml tube and centrifuged. After that, supernatant was obtained, and the amount of TNF-α was measured with a luminex kit The amount was measured and the result is shown in Fig. It has been shown that as the throughput of the ginsenoside complex increases, the production of TNF-a decreases.

(3) Measurement of IL-6 expression

The expression of IL-6 was measured in the same manner as in the measurement of TNF-α expression, and the results are shown in FIG. It was shown that the production of IL-6 was greatly reduced since the throughput of the ginsenoside complex was 1.3 占 퐂 / ml.

(4) Inhibition of the production of nitric oxide (NO)

Nitric oxide production was measured using a NO detection kit (Intron Biotechnology, Korea) in the same manner as described above, and the results are shown in FIG. It was confirmed that the anti-inflammatory effect was excellent because the amount of produced nitric oxide was decreased depending on the treatment amount of the ginsenoside composition of Example 1.

While the present invention has been particularly shown and described with reference to exemplary embodiments thereof, many modifications and changes may be made by those skilled in the art without departing from the spirit and scope of the invention as defined in the appended claims. The present invention can be variously modified and changed by those skilled in the art, and it is also within the scope of the present invention.

<110> BEESEN Bio. Co., Ltd. <120> GINSENOSIDE COMPOSITION FOR TREATING, IMPROVING, OR PREVENTING          INFLAMMATORY DISEASE, AND METHOD FOR PREPARING THE SAME <130> HPC-7597 <160> 1 <170> KoPatentin 3.0 <210> 1 <211> 421 <212> PRT <213> Artificial Sequence <220> <223> 6MT BGL167 <400> 1 Thr Pro Met Thr Asn Pro Phe Pro Gln Asp Phe Leu Trp Gly Val Ala   1 5 10 15 Thr Ala Gly His Gln Val Glu Gly Asn Asn Val Asn Ser Asp Val Trp              20 25 30 Phe Leu Glu His Leu Pro Gly Thr Ile Phe Ala Glu Pro Ser Gly Asp          35 40 45 Ala Val Asp His Tyr His Arg Tyr Arg Glu Asp Ile Ala Leu Ile Ala      50 55 60 Gly Leu Gly Phe Thr Ser Tyr Arg Phe Ser Val Glu Trp Ala Arg Ile  65 70 75 80 Glu Pro Glu Glu Gly His Phe Ser Val Ala Leu Asp His Tyr Lys                  85 90 95 Arg Val Leu Glu Ala Cys Arg Glu His Gly Leu Thr Pro Val Val Thr             100 105 110 Phe His His Phe Ala Ser Pro Leu Trp Leu Leu Arg Ser Gly Gly Trp         115 120 125 Glu Gly Glu Arg Thr Pro Glu Leu Phe Ala Arg Tyr Cys Gly Arg Val     130 135 140 Met Ala His Leu Gly Asp Leu Ile Gly Val Ala Cys Thr Leu Asn Glu 145 150 155 160 Pro Asn Leu Pro Trp Leu Leu Glu Ser Phe Gly Ala Gly Gly Glu Ala                 165 170 175 Pro Glu Asn Arg Gly Lys Val Pro Met Trp Ala Ala Ala Ala Gln Arg             180 185 190 Leu Gly Val Asp Ala Ser Thr Val Ala Pro Phe Trp Phe Cys Ser Thr         195 200 205 Glu Ala Gly Phe Asn Val Lys Leu Ala Ala His Lys Ala Ala Thr Glu     210 215 220 Ala Ile Lys Ala Trp Arg Pro Asp Leu Arg Val Gly Trp Thr Leu Ala 225 230 235 240 Asn Ser Asp Ile Gln Ser Val Pro Gly Gly Glu Glu Ile Ala Ala Gln                 245 250 255 Val Arg Arg Asp Val Asn Glu Arg Phe Leu Glu Ala Ser Arg Gly Asp             260 265 270 Asp Phe Val Gly Ile Gln Thr Tyr Gly Arg Thr Val Tyr Gly Pro Asp         275 280 285 Gly His Ala Pro Ala Pro Glu Gly Val Ala Val Asn Gln Met Gly Trp     290 295 300 Glu Ile Tyr Pro Gln Ala Leu Glu Ala Thr Ile Arg Glu Ala Trp Arg 305 310 315 320 Val Ala Gly Ile Pro Val Met Val Thr Glu Asn Gly Leu Ala Thr Glu                 325 330 335 Asp Asp Thr Gln Arg Val Ala Tyr Leu Arg Thr Ala Val Asp Gly Val             340 345 350 Ala Ser Cys Leu Ala Asp Gly Ile Asp Val Gly Tyr Ile Ala Trp         355 360 365 Thr Ala Phe Asp Asn Phe Glu Trp Ala Ala Gly Tyr Gly Pro Lys Phe     370 375 380 Gly Leu Ile Ala Val Asp Arg Ser Thr Gln Glu Arg Thr Pro Lys Glu 385 390 395 400 Ser Ala Arg Trp Leu Gly Asn Phe Ala Arg Gln Gln Ala Pro Ala Glu                 405 410 415 Ala Pro Gln Pro Ala             420

Claims (7)

The present invention relates to a ginseng extract containing 30 to 70% by weight of total ginsenoside and 0.01 to 4% by weight of Rg3 relative to the total ginsenoside weight as an active ingredient. &Lt; / RTI &gt; The method according to claim 1,
Wherein the ginsenoside composition comprises 2 to 30% by weight of any one selected from Gyp17, Rg3, C-Mc1, C-Mx1 and F2 based on the total ginsenoside weight. A ginsenoside composition for the treatment, improvement or prevention of inflammatory diseases. The method according to claim 1,
The ginsenoside composition according to claim 1, wherein the sum of the weights of Gyp17, Rg3, C-Mc1, C-Mx1 and F2 is 30 to 80% by weight based on the total ginsenoside weight. A ginsenoside composition for the treatment, improvement or prevention of diseases. The method according to claim 1,
Wherein the ginsenoside composition is a pharmaceutical composition for the treatment or prevention of an inflammatory disease or a food composition for improving or preventing an inflammatory disease, the ginsenoside composition for the treatment, improvement or prevention of inflammatory diseases comprising the ginseng extract as an active ingredient . The method according to claim 1,
Wherein said inflammatory disease is selected from the group consisting of inflammatory skin diseases, Crohn's disease, ulcerative colitis, peritonitis, osteomyelitis, meningitis, meningitis, encephalitis, pancreatitis, trauma-induced shock, bronchial asthma, allergic rhinitis, cystic fibrosis, stroke, acute bronchitis, Osteoarthritis, gouty arthritis, systemic lupus erythematosus, recurrent fever, psoriasis, post-infectious arthritis, gonococcal arthritis, tuberculosis, osteoarthritis, osteoarthritis, gout, spondyloarthropathies, ankylosing spondylitis, Wherein the composition is any one selected from the group consisting of arthritis, viral arthritis, fungal arthritis, rheumatoid arthritis, rheumatoid multiple myalgia, arthropathic arthritis, calcium crystalloid arthropathy, non-articular rheumatism, bursitis, For the Treatment, Improvement or Prevention of Inflammatory Diseases Containing Extracts as Active Ingredients Side composition. (a) extracting ginseng with water, a lower alcohol having 1-4 carbon atoms, or a mixed solvent of the lower alcohol and water to prepare a phosphoric acid extract; And
(b) enzymatically treating the phosphoric acid extract with ginsenoside glycosidease comprising the amino acid sequence of SEQ ID NO: 1; and (c) treating the ginseng extract with an effective ingredient. &Lt; / RTI &gt; The method according to claim 6,
One or more selected from the group consisting of ginsenosides Re, Rb1, Rc, Rb2, Rb3 and Rd is partially biotransformed into at least one selected from Gyp17, Rg3, C-Mc1, C-Mx1 and F2 &Lt; / RTI &gt; A method for the preparation of a ginsenoside composition for the treatment, amelioration or prevention of an inflammatory disease.

Images